NASDAQ:GNPX

Genprex Q2 2026 Earnings Results & Report

Genprex logo
$1.45 -0.22 (-13.17%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$1.48 +0.03 (+1.72%)
As of 11/20/2026 06:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Genprex reported Q2 2026 earnings on August 14, 2026. The company reported EPS of -$9.40.

Earnings Announcement Details

Quarter
Q2 2026
Report Date
Time
Before Market Opens

Genprex EPS Results

Actual EPS
-$9.40
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Genprex Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

Genprex's next earnings date is estimated for Wednesday, December 2, 2026, based on past reporting schedules.

Genprex Q2 2026 Earnings FAQ

Genprex (NASDAQ:GNPX) reported earnings of -$9.40 per share for Q2 2026. The report was announced on Friday, August 14, 2026.

Genprex's next earnings date is estimated for Wednesday, December 2, 2026. MarketBeat tracks confirmed and estimated earnings dates for Genprex on the company's earnings history page.

Genprex Earnings Headlines

Financial legend: “This is bad, really bad...”
Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leading Weiss Ratings, the only conflict-free rating agency in the US. Now he says a $3 trillion problem could trigger a chain reaction of crashes and failures, causing a global freeze in financial markets.tc pixel
See More Genprex Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Genprex? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Genprex and other key companies, straight to your email.

About Genprex

Genprex (NASDAQ:GNPX), Inc. is a clinical-stage gene therapy company developing treatments for cancer and diabetes. The company is based in Austin, Texas, and its work focuses on using genetic material to address diseases with significant unmet medical needs.

Its lead cancer candidate, REQORSA (quaratusugene ozeplasmid), is an investigational, non-viral gene therapy designed to deliver the TUSC2 tumor-suppressor gene to cancer cells. Genprex has studied REQORSA in clinical trials for non-small cell lung cancer, including in combination with other cancer therapies.

Genprex is also developing an investigational gene therapy program for diabetes. Its candidates remain in development, and the company’s therapies are not approved for commercial use.

View Genprex Profile